Rare diseases & IEM products

Glutaric Aciduria is an inherited metabolic disease that involves the metabolism of three amino acids: lysine, hydroxylisine and tryptophan. Amino acids are the constituent units of proteins and are therefore daily taken as part of one’s diet. Individuals with Glutaric Aciduria type 1 should be on a lysine-free and low-tryptophan diet. Given the impossibility of excluding these amino acids from natural proteins, the patient should, in general, follow a protein-free diet, supplemented with adequate protein substitutes (free from lysine and with a low tryptophan content). The treatment is, however, customized according to the needs of the individual patient.

 

GA Medimicro 3H

GA Medimicro 3H

GA Medigel

GA Medigel

Classical homocystinuria is an inherited metabolic disease characterized by the deficiency of an enzyme involved in the methyl metabolic pathway of the amino acid methionine. This deficiency leads to the accumulation of the amino acid homocysteine ​​in the blood and urine. Amino acids are the constituent units of proteins and are therefore daily taken as part of one’s diet. Individuals with classic homocystinuria should follow a low-methionine diet.
Given the impossibility of excluding this amino acid from natural proteins, the patient should, in general, follow a protein-free diet, supplemented with adequate protein substitutes (without methionine). The treatment is, however, customized according to the needs of the individual patient.

 

HOM Medimicro 3H

HOM Medimicro 3H

HOM Medigel

HOM Medigel

Isovaleric Aciduria is an inherited metabolic disease related to the metabolism of the amino acid leucine.
Amino acids are the constituent units of proteins and are therefore daily taken as part of one’s diet. Individuals with Isovaleric Aciduria should follow a diet that does not contain the amino acid leucine, in order to minimize isovaleric acid formation.
Given the impossibility of excluding this amino acid from natural proteins, the patient, in general, should follow a protein-free diet, supplemented with adequate protein substitutes (without leucine).

 

IVA Medimicro 3H

IVA Medimicro 3H

IVA Medigel

IVA Medigel

Methylmalonic Aciduria and Propionic Aciduria are hereditary metabolic diseases related to the metabolism of some amino acids. Amino acids are the constituent units of proteins and are therefore taken daily as part of one’s diet. Individuals with Methylmalonic or Propionic Aciduria should follow a diet free from the amino acids involved in the pathology (methionine, threonine and valine) and should also take a reduced amount of the amino acid isoleucine. Given the impossibility of excluding these amino acids from natural proteins, the patient should, in general, follow a protein-free diet, supplemented with adequate protein substitutes (not containing methionine, threonine and valine and with a low content of isoleucine). The treatment is, however, customized according to the individual patient’s protein needs.

 

MMA/PA Medimicro 3H

MMA/PA Medimicro 3H

MMA/PA Medigel

MMA/PA Medigel

MSUD is a hereditary metabolic disease, characterized by the inability of the individual affected to metabolize branched chain amino acids (leucine, isoleucine and valine).
Amino acids are the constituent units of proteins and are therefore daily taken as part of one’s diet. Individuals suffering from Leucinosis should follow a diet without amino acids which fail to metabolise (leucine, isoleucine and valine).
Given the impossibility of excluding these amino acids from natural proteins, the patient will, in general, have to follow a protein-free diet, supplemented with adequate protein substitutes (which do not contain leucine, isoleucine and valine).

 

MSUD MediMicro 3H

MSUD MediMicro 3H

MSUD MediGel

MSUD MediGel

PKU is a condition characterized by the inability of the individual affected to metabolize the specific amino acid, phenylalanine. Amino acids are the constituent units of proteins and are taken daily in one’s diet. Persons affected by PKU should follow a phenylalanine-free diet, in order to avoid the appearance and progression of the symptomatic profile of this disease. Given the impossibility of excluding a specific amino acid from natural proteins used in food, the PKU patient should, in general, follow a protein-free diet and integrate it with adequate protein substitutes (i.e those not containing phenylalanine). The treatment is, however, customized according to the needs of the individual patient.

 

Afenil Medi15

Afenil Medi15

Afenil GMP UP Shake

Afenil GMP UP Shake

Afenil Lime

Afenil Lime

Afenil Bar GMP-Up

Afenil Bar GMP-Up

Neutrafenil Micro R

Neutrafenil Micro R

Afenil Micro 3H

Afenil Micro 3H

Afenil Gel

Afenil Gel

Afenil 1

Afenil 1

Type 1 tyrosinemia is an inherited metabolic disease characterized by the inability of the individual affected to metabolize a specific amino acid, tyrosine. Amino acids are the constituent units of proteins and are therefore daily taken as part of one’s diet. Individuals with type 1 tyrosinemia should follow a diet that is free from tyrosine and another amino acid involved in the disease, phenylalanine, as a precursor to tyrosine. Given the impossibility of excluding these amino acids from natural proteins, the patient should, in general, follow a protein-free diet, supplemented with adequate protein substitutes (without tyrosine and phenylalanine). The treatment is, however, customized according to the needs of the individual patient.

 

TYR Medi15

TYR Medi15

TYR Medimicro 3H

TYR Medimicro 3H

TYR Medigel

TYR Medigel

Urea Cycle Defects are a group of inherited metabolic diseases, characterized by deficiencies in enzymes and transporters involved in the urea cycle, a metabolic pathway dedicated to the transformation of ammonium (produced by the catabolism of amino acids) into urea, which in turn is eliminated from the body via urine. Some forms of UCD can be treated exclusively through restricting food proteins, in order to reduce the amount of ammonium deriving from their catabolism. However, a low-protein diet may not be able to provide the right amount of essential amino acids that the body needs; for this reason, the patient suffering from urea cycle defects should supplement a low-protein diet with a mix of essential amino acids. Moreover, in some cases it is necessary to intervene with a specific pharmacological treatment that supports the removal of ammonium.

 

UCD Medimicro 3H

UCD Medimicro 3H

UCD Medigel

UCD Medigel

Adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN) are two variants of a progressive disease that damages the nervous system. The disease is hereditary. “Adreno” refers to the adrenal glands, “leuko” means white and refers to the white substance (myelin) in the nervous system, and “dystrophy” means wasting away. In adrenomyeloneuropathy, “myelo” refers to the spinal cord, and “neuropathy” indicates that the disease affects the peripheral nerves.

 

Aldixyl

Aldixyl

Mats Erasmie

Mats Erasmie

Chairman of the board Simplex Motion AB. Consultant in Leadership and Business Development, Erasmie&Erasmie AB.

Key Competence

Sales, Leadership as a part of a strategic changes.

Education
  • MBA, International marketing, University of Stockholm.
  • Certified in Authentic Leadership,Transaction Analysis, Situational Leadership (SL II, Blanchard)
  • Certifed in Insight Discovery, Certifed in DISC
Experiences
  • Consultant in Leadership and Business Development.
  • Erasmie&Erasmie AB.
  • Chairman of the board Simplex Motion AB.
  • Consultant at Booster Group AB, business development and negotiations.
  • Teacher at IHM, Market Analysis, Practical Marketing and Negotiations.
  • CEO, Chairman of the board and partner; Sällma AB.
  • Vice President Marketing & Sales, Consultant in Leadership and Business.
  • Development at Cordovan Performance Sweden AB.
  • CEO at Lucky Punk AB.
Publications

Books and training packages, marketing and sales, twelve in total since 1999

  • ”MED KUNDEN I FOKUS”, Liber Ekonomi 2000
  • ”KUNDRELATIONEN”, Liber Ekonomi 2001
  • ”FÖRSÄLJNING OCH SERVICE”, Liber Ekonomi 2003
  • ”PERSONLIG FÖRSÄLJNING 1”, Liber Ekonomi 2012
  • ”PERSONLIG FÖRSÄLJNING 2”, Liber Ekonomi 2014
  • ”Dödskaravanen”, Historical novel, 2018
  • ”Silverfloden”, Historical novel, 2019
  • Various articles in the magazines Ledarskap, Affärsvärlden and Dagens Industri.

What Now?

You have defined your interest area and the questions related to this.

Now fill in the form and send it to us. The defined contact person from GHN Pharma Nordic will review your interest and contact you within 48 hours.

Get a Contact Person

Pontus Bergman

Valdet Hetemi

Head of Operation & Logistics

Key Competence

Over 17 years of experience within the Pharmaceutical industry; Rx, Medical Devices, Metabolic Diseases, OTC, Logistics and Supply Chain, Business Strategy, Finance, Sales and Marketing, Start-Ups.

Education
  • Education: Master of Business Administration and Bachelor of Social Sciences from the University of Lund and University of Cologne.
Experiences
  • Head of Operations at POA Pharma Scandinavia AB, Country Manager Sweden at Vitaflo Scandinavia AB/ Navamedic AB, Finance Manager at Vitaflo Scandinavia AB/Navamedic AB.

Ingvar Bosaeus

Martin Svahn

RP& Pharmacist

Key Competence

Martin Svahn is a licensed pharmacist and pharmacy manager.

Education

Licensed Pharmacist at the Universitet of Uppsala, Magisterthesis at the Departement of Anaesthesiology,,University of Uppsala. Master's Program in Clinical Pharmacy University of Uppsakla.

Experiences
  • Start-up of a new privately owned pharmacy. . Worked in 2013 at K3 as GSST, Since 2014 pharmacy manager at three pharmacies with responsibility for 13-20 employees and an annual turnover of 80 million. "Cluster manager" for Kronan's pharmacy Halland.
Mats Erasmie

Andreas Larsson

Finance Manager

Key Competence

Experience within the Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases and OTC regarding Accounting and Finance Strategy, Financial reporting, Business Development and Logistical support

Education
  • Master of Aeronautical Science at the University of Embry-Riddle Aeronautical University and a degree at the KY academy of finance and accounting at Studium in Gothenburg.
Experiences
  • Accounting manager at POA Pharma Scandinavia AB, POA Pharma North America and Adrian & Partners AB.

Pontus Bergman

Pontus Bergman

PB Lawyer, founder of Bergman & Eek Advokat AB.

Key Competence

Principal felds of practice are strategically planning for privately owned companies regarding all legal and economical matters. Special focus on developing and establishing new companies or activities abroad, including international tax law for companies and employees.

Education
  • Education: Master of Law from University in Lund
Experiences
  • Partner at Setterwalls Law Firm
  • Member of the board of POA Pharma AB and in several Swedish privately-own companies.

Tina Madsen Sandström

Tina Madsen Sandström

CEO GHN Pharma AB

Key Competence

Over 35 years experience within the international Pharmaceutical industry Rx, Medical Devises, OTC and   Rare Metabolic Diseases. Administration, Leadership, , Licenses & Acquisitions, Start-ups Development, Development, Management, Leadership.

 

Education

Merkonom, Educated at Hillerød Business School

Experiences
  • Managing Director for Pharma-Vinci A/S, Member of the branch organisation BFID
  • CEO Vitafo Scandinavia AB
  • CEO POA Pharma Scandinavia AB
  • Director of the board Vitafo Scandinavia AB
  • Director of the board POA Consulting AB
  • Director of the board POA Pharma Scandinavia AB
Roland Sandström

Roland Sandström

COB GHN Pharma AB

Key Competence

45 years experience within the international Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases, OTC. Commercial Strategy, Business Development, License & Acquisitions, Start-ups Development,Management, Organisation Theory.

Education

Master of Political Science at the University of Lund

Experiences
  • Managing Director Meda Sweden
  • Board member of LSAB and LIF
  • COB Vitafo Scandinavia AB
  • Director of the board Navamedic
  • COB POA Consulting Scandinavia AB
  • COB POA Pharmas Scandinavia AB
  • COB POA Pharma North America
Publications
  • Kunden som Kompis (Customer as a Pal)
  • Articles around Project work, organisation theory and marketing
  • Lectures and abstract publications at IPMA in Paris and Ljubljana